Dehydrated Human Amnion/Chorion Membrane (dHACM) Allografts as a Therapy for Orthopedic Tissue Repair

Jennifer Lei, PhD,* Lauren B. Priddy, PhD,† Jeremy J. Lim, PhD,* and Thomas J. Koob, PhD*

Summary: The amniotic membrane is a placental tissue that supports the development of the fetus during pregnancy. It is composed of extracellular matrix components such as collagen, fibronectin, and laminin, and contains many different growth factors and cytokines. Amniotic membrane can be PURION® Processed to produce dehydrated human amnion/chorion membrane (dHACM, Epifix, Amniofix; MiMedx Group Inc.) allografts. This tissue has been shown in randomized clinical trials to be effective for healing chronic foot and leg ulcers, and has demonstrated the ability to promote the migration of stem cells in vitro and to recruit stem cells to a wound site in vivo. Owing to its regenerative properties, amniotic membrane and dHACM allografts have more recently been implicated as an alternative or supplemental therapy in the treatment of orthopedic tissue injuries such as plantar fasciitis, tendinopathy, and vertebral fusion prostheses. The amniotic membrane is composed of 2 distinct layers that surround the embryo: the amnion that lines the inner surface of the amniotic sac interfacing with the fetus, and the chorion that is the outer layer in contact with maternal tissue. The amnion layer is composed of an epithelial layer, a basement membrane, a compact layer, and a fibroblast layer. Collagens type I and type III are located in the fibroblast layer and provide most of the tissue’s mechanical strength. Collagen type V and VI create filamentous cross-links between the fibrous network and the basement membrane that contains collagen type IV. Other extracellular matrix (ECM) components, such as fibronectin and laminin, are found throughout the amnion tissue. An intermediate spongy layer separates the amnion and chorion with a jelly-like network rich in collagen III, proteoglycans, and glycoproteins. The chorion layer is composed of a reticular layer containing collagens I, III, IV, V, and VI and proteoglycans; a basement membrane layer containing collagen IV, fibronectin, and laminin; and a trophoblast layer. Together, the amniotic membrane is a fibrous tissue containing many ECM components (Fig. 1). Some of the many factors present in this bioactive ECM include platelet-derived growth factors (PDGFs), transforming growth factor-β1 (TGF-β1), basic fibroblast growth factor, and granulocyte colony-stimulating factor, as well as interleukin-4 (IL-4), IL-6, IL-8, and IL-10. The crucial roles of these metabolically active tissue are to function as a barrier for water and soluble material transport, to synthesize growth factors and cytokines, and to regulate amniotic fluid pH.

AMNIOTIC MEMBRANE

Structure and Function of Amniotic Membranes

The placenta plays a critical role in transporting nutrients and protecting the fetus during pregnancy. The developing fetus and amniotic fluid are enclosed in the amniotic sac of the placenta, circumscribed by the amniotic membrane, which functions to help modulate the contents of the intra-amniotic compartment and mediates the interaction between the fetal and maternal tissues. The amniotic membrane is composed of 2 distinct layers that surround the embryo: the amnion that lines the inner surface of the amniotic sac interfacing with the fetus, and the chorion that is the outer layer in contact with maternal tissue. The amnion layer is composed of an open-access article published under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

*From the *MiMedx Group Inc., Marietta, GA, and ?Department of Agriculture and Biological Engineering, Mississippi State University, Starkville, MS.
Supported by MiMedx Group Inc.
For reprint requests, or additional information and guidance on the techniques described in the article, please contact Jennifer Lei, PhD, at lei@midmedx.com or by mail at MiMedx Group Inc., 1775 West Oak Commons Court NE, Marietta, GA 30062. You may inquire whether the author(s) will agree to phone conferences and/or visits regarding these techniques.

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Website, www.techortho.com. Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Techniques in Orthopaedics® • Volume 00, Number 00, 2017 www.techortho.com | 1
Tissue Human Amnion Chorion (dHACM) as defined by enhanced angiogenesis was demonstrated in response to dHACM model, increased hematopoietic stem cell recruitment and implants.29 These studies demonstrate that dHACM contains membrane tissue that has been cryomilled and sieved using both membrane form and micronized form, in which the latter contains cells, and stem cells to promote tissue healing and repair.7,26,27 To stimulate paracrine responses in fibroblasts, endothelial chemokines, and protease inhibitors, many of which function studies have identified over 226 growth factors, cytokines, administered to patients as a flowable allograft. Previous tissue is typically reconstituted in a saline solution and DOM; Applied Biologics), and “placental tissue matrix” (PX50; Skye Biologics) was measured using a multiplex enzyme-linked immunosorbent assay array by an independent contract research organization. Detailed methods containing how this analysis was performed is available in the Supplemental Information, DOM; Applied Biologics), and “placental tissue matrix” (PX50; Skye Biologics) was measured using a multiplex enzyme-linked immunosorbent assay array by an independent contract research organization. Detailed methods containing how this analysis was performed is available in the Supplemental Information, Supplemental Digital Content 1, http://links.lww.com/TIO/A5. The results presented are shown as the measured concentration of a factor in either product normalized to the measured concentration in micronized dHACM (denoted by the horizontal blue line at 100%). It was observed that 48 of the 64 factors that were detected in micronized dHACM were not detected in the “amnion and amniotic fluid” product, and of the factors detected in both products, 14 of 16 factors were measured at significantly greater levels in micronized dHACM (Fig. 2; P<0.05). When comparing micronized dHACM to the “placental tissue matrix” product, 54 of the 64 factors detected in micronized dHACM were not detected in the placental tissue matrix, and of those detected in both, 8 of 10 factors were found to be significantly greater in micronized dHACM (Fig. 3; P<0.05). Overall, 62 of 64 factors (96.8%) were measured at levels significantly higher in micronized dHACM compared with both the “amnion and amniotic fluid” and the “placental tissue matrix” products (Figs. 2, 3). In total, these products contained only 1% to 2% of the total content of growth factors, cytokines, and chemokines that dHACM contained, suggesting that dHACM retains high levels of growth factors, cytokines, and chemokines that can be delivered to promote soft tissue healing. Owing to their rich biological content—a cocktail of growth factors and cytokines, including immunomodulatory molecules—as well as the structural integrity afforded by the abundance of collagens and proteoglycans, amniotic membrane may be beneficial in many orthopedic soft tissue healing applications.

**dHACM Clinical Applications**

Overall, hundreds of thousands of PURION Processed dHACM grafts have been utilized clinically to promote healing in a variety of applications including skin and corneal wounds, periodontal surgery, and soft tissue repair, with no known adverse events as a result of the use of these tissues.11,31 Recently, amniotic membrane sheets processed by this method demonstrated greatly improved healing of diabetic foot ulcers15 and venous leg ulcers16 compared with the clinical standard compression therapy in randomized controlled clinical trials.

Diabetic foot and venous leg ulcers, lower extremity complications that commonly occur in people with poor circulation and neuropathy, are slow healing chronic wounds that can result in severe morbidity.31 In a randomized controlled trial of amniotic membrane grafts, patients with diabetic foot ulcers were either given standard of care treatment with a collagen-alginate dressing or standard of care treatment with dHACM application every 2 weeks. After 4 weeks, wound size was reduced 97.1%± 7% in patients receiving dHACM treatment, compared with the 32.0%± 47.3% closure in patients receiving standard of care treatment.19 By week six, 12 of 13 patients

---

receiving dHACM treatment reported healed ulcers compared with only 1 of 12 patients receiving standard of care treatment. In addition, wounds did not recur with long-term follow-up after up to 12 months demonstrating robust healing and repair.32 In a study comparing dHACM application to standard compression therapy for venous leg ulcers, 62% of the patients receiving the allograft exhibited more than 40% wound closure after 4 weeks, which was significantly greater than 32% of patients receiving compression therapy.11 Forty percent closure was validated as a predictive end point with 80% of venous leg ulcers undergoing 40% closure within 4 weeks progressing to complete closure within 24 weeks, compared with an only 33% healing rate of wounds with <40% closure.33 Overall, it has been observed that for both diabetic foot ulcers and venous leg ulcers, application of membrane dHACM is an effective therapy to heal chronic wounds rapidly and has significant improvements compared with standard therapies.12,33,34 Although dHACM allografts have typically been used to heal chronic dermal wounds, their regenerative properties with the ability to reduce scar tissue formation, modulate inflammation, and enhance healing make them a potentially effective treatment option for healing of other tissues.

**ORTHOPEDIC TISSUE HEALING**

Orthopedic soft tissue healing occurs in similar process to wound healing. The 3 main phases are the inflammatory phase, the proliferation phase, and the remodeling phase. The initial inflammatory phase occurs immediately after the injury and can last up to 1 to 3 days, during which increased blood flow helps increase fibrin clot formation and form a mesh to trap any foreign particles and debris. Mast cells and neutrophils are recruited to the site to help phagocytose damaged tissue or debris and release cytokines, such as tumor necrosis factor-α, IL-1α, IL-1β, TGF-β1, granulocyte colony-stimulating factor, and macrophage colony-stimulating factor. These cytokines help recruit other inflammatory cells, such as monocytes/macrophages and lymphocytes, that stimulate the proliferative phase of the healing process.35 The proliferative phase begins 24 to 48 hours after injury and persists for 2 to 3 weeks. During the proliferation phase, resident tissue cells migrate to the area from surrounding tissues and are activated by factors released by local macrophages. Upon activation, these cells, which include fibroblasts for fibrous tissues or local stem cells,
proliferate and secrete disorganized collagen-based tissue. In addition, secretion of factors such as macrophage-derived factors, PDGF, and FGF result in the formation of developing capillaries and angiogenesis of the scar tissue. Resolution of tissue healing ends with the remodeling phase that results in the formation of organized collagen fibers that resembles the original tissue as closely as possible. The initial deposition of collagen fibers during the proliferative phase are relatively weak fibrils; therefore, during remodeling, the fibers organize and align themselves in the direction of local stresses to create a fibrous tissue that may not exactly recapitulate the original tissue structure, but does restore full functional utility.

Although tissue healing is a complex process, therapies that can intervene or support such events can be beneficial to the repair process to produce the best quality tissue in minimal time. Appropriate interventions, such as modulating the inflammatory response to maximize recruitment of cells or refining the scar tissue formation during the proliferative and remodeling phases, can be used to effectively produce a healed tissue that best resembles the structure and function of the original tissue before injury.

**AMNIOTIC MEMBRANE APPLICATIONS FOR ORTHOPEDIC TISSUES**

Typically, for orthopedic tissue injuries, current repair techniques often only address restoring mechanical function by reattachment or replacement of the tissue. For example, tendon and ligament repair in knee joints use autografts or allografts to physically reconnect the tissue. Although the patient may exhibit decreased pain and return to functional usage at the site of injury, the biological structure of that tissue is not reproduced, which can increase the potential for future reinjury. By using alternative methods to both restore function and regenerate tissue with structure similar to that of its native form, both repair and regeneration of injured orthopedic tissues can potentially be achieved.

Alternative methods of repairing orthopedic tissues involve the application of bioactive factors, such as tissue engineering strategies using growth factors, scaffolds and stem cells, that can promote healing and regeneration of the tissue itself. The amniotic membrane is a natural ECM biomaterial that contains many growth factors, cytokines, proteases, and regulatory inhibitors that can contribute to the process of soft tissue healing. dHACM allografts have shown clinical success in healing poorly vascularized chronic wounds and therefore have promising potential to also promote healing in less vascularize orthopedic tissues like tendon, ligament, and cartilage. Owing to these characteristics, amniotic membrane allografts have recently been used in soft orthopedic tissues and spine applications to reduce pain, prevent scar tissue formation, and promote healing. An overview of clinical usages of dHACM for repair of orthopedic tissues is summarized in Table 1.

**Tendon and Ligament Repair**

The incorporation of amniotic membranes tissues can decrease fibrous collagen deposition scar formation in vitro and modify inflammatory responses of tenocytes. Compared with adult wound healing, fetal wound healing has the ability to form highly aligned and organized fibers with minimal scar formation, suggesting that fetal tissues and the fetal environment may be uniquely capable of supporting tissue regeneration. Therefore, one approach to recapitulate fetal healing is to use ECM-based biomaterials that originate from environments with anti-inflammatory and antimicrobial properties, such as amniotic tissue. It was shown that when amniotic membrane tissue was incorporated into tenocyte-laden collagen-glycosaminoglycan scaffolds, cells exhibited increased metabolic activity in both basal and proinflammatory environments (induction with IL-1β) compared with scaffolds without amniotic tissue. In addition, the addition of amniotic membranes also downregulated the gene expression of the proinflammatory molecules tumor necrosis factor-α and matrix metalloprotease-3 in tenocytes, indicating that this biomaterial could alter the inflammatory response associated with scar formation in tendon healing to better mimic fetal soft tissue healing.

Methods of incorporating hyaluronic acid (HA) have also been explored to reduce scar formation, as HA is known to play a role in chronic wound healing by promoting cell proliferation and motility. As a critical component of several orthopedic tissues including cartilage and synovial fluid, HA contributes both mechanical properties as well as the ability to regulate cellular activity through interaction with growth factors and binding of cell surface receptors, such as CD44. In particular, HA is an ECM component that has been detected and quantified in dHACM tissues and may play a role in improved soft tissue healing. Thus, the use of amniotic membranes that contain HA could potentially be an effective method to help modulate the inflammatory environment to decrease scar formation during tendon and ligament healing. In flexor tendon transection models in chickens, it has been shown that the use of amniotic membranes can improve flexor tendon repair. Zone II flexor tendon injuries can lead to loss of hand functions due to the formation of fibrous adhesions and restriction of tendon gliding. One approach to prevent tissue adhesion formation is to use membranous materials, such as amniotic membrane allografts, which can act as a barrier between the healing tendon and the surrounding tissue environment. In white leghorn chickens, digital flexor tendons were incised and repaired with a modified Kessler stitch, and amniotic membrane was sutured to the tendon proximally and distally away from the cut ends, ultimately surrounding the repaired tendon tissue. By week 12, histologic analysis revealed that tendons covered with the amniotic membrane did not exhibit granulation tissue or fibrous adhesions, as was observed with groups without amniotic membrane intervention. In addition, organized, aligned collagen fibers were observed throughout the healed tendon. Using the Tang scale to evaluate adhesion formation, it was determined that amniotic membrane coverage was beneficial in preventing adhesion when compared with repaired tendons without the graft. Collectively, these data demonstrate that the amniotic membrane can be used to assist in the treatment of reconstructed tendons and prevention of adhesions.

Clinical applications of dHACM for tendon and ligament tissue repair have recently been used in the treatment of plantar fasciitis, anterior cruciate ligament (ACL) reconstruction, rotator cuff injury, tennis elbow, and Achilles tendinopathy (Table 1). For treatment of plantar fasciitis, a prospective, randomized, blinded clinical trial with 45 patients revealed that micronized dHACM administration is a viable treatment option to decrease pain. Micronized dHACM was first constituted in 0.9% saline at 0.5 or 1.25 cc. For administration of either the dHACM treatment or saline control, patients received a 2 cc injection of Marcaine to the medial origin of the plantar fascia, followed by an injection of 0.9% saline control or 0.9% saline containing the reconstituted micronized dHACM. The needle was placed down to the periosteum of the heel and the treatment was delivered. Using the American Orthopaedic Foot and Ankle Society Hindfoot Scale, it was observed that patients receiving either 0.5 or 1.25 cc of dHACM injection significantly increased their score when
TABLE 1. Case Study Examples of dHACM Clinical Applications for Treatment of Orthopedic Injuries

<table>
<thead>
<tr>
<th>Application</th>
<th>Injury</th>
<th>dHACM Administration</th>
<th>Amount Administered</th>
<th>Patient Size</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tendon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supraspinatus tendon tear</td>
<td>dHACM injection supplemented after tendon reattahclment</td>
<td>NA</td>
<td>1</td>
<td>Rotator cuff strength returned to normal after 7 wk</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Common extensor tendon tear</td>
<td>dHACM injection 8 and 11 mo after injury diagnosis</td>
<td>40 mg</td>
<td>1</td>
<td>80% reduction of symptoms after 1 treatment; complete resolution after second treatment</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Lateral epicondylitis</td>
<td>Single dHACM injection immediately after injury diagnosis</td>
<td>0.5 cc</td>
<td>5</td>
<td>4/5 patients reported reduced symptoms after 3 mo</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Patellar tendon partial tear</td>
<td>Single dHACM injection 6 mo after injury diagnosis</td>
<td>40 mg</td>
<td>1</td>
<td>Patient reported &gt;90% improvement of symptoms after 5 wk</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Supra/infraspinatus tendinitis and partial tears</td>
<td>Single dHACM injection 8 mo after injury diagnosis</td>
<td>40 mg</td>
<td>1</td>
<td>Ultrasound revealed soft tissue healing and patient reported reduced symptoms by &gt;90% after 4 mo</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Ligament</td>
<td>Achilles tendinopathy</td>
<td>Single dHACM injection 1 mo after injury diagnosis</td>
<td>100 mg</td>
<td>22</td>
<td>72.7% patients experienced decreased pain with corresponding increases in activity and function</td>
<td>47</td>
</tr>
<tr>
<td>ACL reconstruction</td>
<td>Hamstring autograft augmented with dHACM allograft patch</td>
<td>Patch</td>
<td>1</td>
<td>MRI revealed vascularization of autograft and continued healing 6 mo postoperation; patient returned to normal gait after 10 wk and returned to full sports activity after 8 mo</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Chronic and refractory plantar fasciitis</td>
<td>Single dHACM injection after 10 mo of persistent pain</td>
<td>40 mg</td>
<td>10</td>
<td>Ultrasound revealed 19% decrease in thickness of fascia; 10/10 patients reported significantly reduced pain after 4 mo</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Plantar fasciitis</td>
<td>Single dHACM injection after 12 mo of traditional treatments</td>
<td>0.5 or 1.25 cc</td>
<td>44</td>
<td>At weeks 1-8, patients reported significantly lower AOFAS hindfoot pain scores compared with control patients</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Plantar fasciitis</td>
<td>Single dHACM injection</td>
<td>40 mg</td>
<td>20</td>
<td>16/20 patients reported complete pain reduction after 3 mo; 17/20 patients reported improvement in activity and function after 3 mo</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Spine</td>
<td>TLIF</td>
<td>dHACM membrane placed in epidural space after insertion of fusion device</td>
<td>Patch</td>
<td>5</td>
<td>After 12 mo, dHACM barrier appeared to reduce epidural fibrosis; patients reported significantly decreased Oswetry Disability Index scores compared with scores before surgery, indicating lower back pain levels</td>
<td>51</td>
</tr>
</tbody>
</table>

Data gathered from clinical trial reports, poster presentations or internal clinical reports. Patient data were collected and performed under informed consent and approval of an institutional review board was obtained.

ACL indicates anterior cruciate ligament; AOFAS, American Orthopaedic Foot and Ankle Society; dHACM, dehydrated human amnion/chorion membrane; NA, data not available; ODI, Oswetry Disability Index; TLIF, transformaminal lumbar interbody fusion.

compared with baseline scores and had significantly greater scores when compared with patients receiving the control saline treatments. This increase in score represented decreased pain and greater function in the foot. Owing to the many growth factors contained in the dHACM tissue, biomolecules such as EGF, TGF-β, FGF, and PDGF-AA and PDGF-BB may stimulate cell migration and proliferation, as well as metabolic processes such as collagen synthesis to help initiate tendon healing. In another case study, a dHACM allograft patch was used to supplement a ruptured ACL that was reconstructed using a hamstring autograft. During the arthroscopic ACL reconstruction procedure, the hamstring autograft was augmented with a dHACM allograft patch fixed using the Tape Locking Screw (TLS) technique. The autografts were wrapped in dHACM and rolled around 2 posts to form a 4-strand closed loop with TLS strips passed through 2 ends of the tendon loops. Subsequent magnetic resonance imaging scans revealed vascularization in the hamstring graft tissue as early as 3 months post-operative and the patient’s rehabilitation progressed successfully with regards to strength and proprioception at 8 months post-operative. Although the sample size was small for this study, this represents another example of dHACM uses in clinical practices for treatment of tendon and ligament injuries.

Taken together, recent preclinical and clinical findings suggest that the administration of dHACM allografts is a viable option to treat tendon and ligament injuries. The ability to modulate the cellular inflammatory environment may decrease pain and promote scarless healing without the formation of fibrous tissue, thus supporting the regeneration of injured tendon tissues. In addition, dHACM may be beneficial as an adjuvant, based on the success of clinical cases of tendon and ligament healing when dHACM allografts have supplemented repair treatments.
Cartilage and Joint Space Repair

Amniotic membrane has demonstrated potential for cartilage healing/regeneration in in vitro and in vivo models. Human articular chondrocytes cultured on the basement membrane of cryopreserved human amnion maintained viability and migrated into cartilage tissue explants. In addition, hybrid, 3-dimensional, cell-seeded scaffolds composed of homogenized, lyophilized amniotic membrane, and fibrin supported both maintenance of chondrocyte phenotype and glycosaminoglycan production. Lastly, scaffolds containing rabbit chondrocytes seeded on the stromal layer of human amnion led to collagen type II production in vitro, and repair of osteochondral defects after 8 weeks in a rabbit model. These studies represent examples of amniotic membrane usages in tissue engineering applications to help support cell-based healing of cartilage tissue both in vitro and in vivo.

Synoviocytes found within the lining of the joint capsule (synovial membrane) are known to maintain homeostasis of the joint space by producing specialized matrix components, such as HA, collagens, and fibronectin into the synovial fluid. In degenerative joint diseases, such as osteoarthritis (OA) and rheumatoid arthritis (RA), cartilage undergoes loss of proteoglycans and disruption of collagen fibers, whereas synoviocytes often exhibit hyperplasia. Treatments of intra-articular HA injection have been shown to be effective in reducing pain in patients with OA, potentially due to HA's ability to reduce nerve impulses and nerve sensitivity associated with pain. Furthermore, it has been shown that HA has chondroprotective effects, in which HA binding to CD44 can stimulate chondrocyte production of tissue inhibitors of matrix metalloproteinases (TIMPs) that inhibit cartilage degradation and promote cell proliferation and ECM production. When examining effects of extracts of micronized dHACM on synoviocytes harvested from synovium of donors without arthritic disease, donors with OA and donors with RA (cell applications) it was observed that micronized dHACM extracts promoted significant upregulation of HA synthase (HAs) 1 and 2 gene expression over the course of 3 days in all 3 cell types when compared with nontreated cells (basal and complete) (Fig. 4). Methods for the experimental setup of these experiments can be seen in the Supplemental Information, Supplemental Digital Content 1, http://links.lww.com/TIO/A5. In addition, it was observed that HA production significantly increased in synoviocytes from RA synovium when treated with the lower dosage (1 mg/cc) of dHACM extracts (Fig. 4). Although the exact mechanism of HA production by the synoviocytes is not clear, it is known that endogenous synthesis of HA can be stimulated by supplementation with an external source of HA and TGF-β1, EGF and IL-1β. Therefore, the upregulation in HA synthase expression could be caused by the stimulation of the HA, growth factors, and cytokines contained within the allograft tissue. The administration of dHACM for treatment of joint diseases could be potentially effective in reducing pain and regenerating tissue due to the delivery of HA and other ECM components, as well as the cocktail of bioactive growth factors and inhibitors found in the tissue allograft.

In a medial meniscal transection-induced model of OA in Lewis rats, micronized dHACM injected intra-articularly slowed the progression of the disease. Histologic staining at day 3 and at day 21 revealed that the micronized dHACM...
allograft incorporated into the surrounding synovial tissue soon after administration and remained localized to the joint for up to 21 days. Using equilibrium partitioning of an ionic contrast agent micro-computed tomography imaging, no cartilage lesions were measured, and both the number of partial erosions and proteoglycan loss were significantly reduced at 21 days in animals receiving micronized dHACM treatment compared with saline-treated control medial meniscal transaction animals. Possible mechanisms by which dHACM administration can attenuate cartilage degradation and OA progression is through the delivery of a cocktail of growth factors (PDGF, TGF-β, basic fibroblast growth factor, EGF, placental growth factor), anti-inflammatory molecules (IL-4, IL-10), TIMP-1, TIMP-2, and TIMP-4, as well as ECM components contained in dHACM tissue. These biomolecules can potentially maintain cartilage homeostasis, reduce inflammation, and reduce matrix metalloproteinase expression that is active in diseased joints. Collectively, in vitro data suggest that amniotic membrane may serve as an effective scaffold for cell delivery in cartilage tissue engineering applications and can act as a supportive ECM platform to promote cartilage repair. Preclinical data also revealed that dHACM allografts can be administered as a disease modifying therapy for OA. In both cases, the utilization of amniotic membrane, specifically dHACM allografts, can be beneficial in therapies for cartilage injury and disease.

Spinal Repair

Similarly to its function in situ, amniotic membrane, in particular dHACM, has been used successfully during surgical procedures as a barrier membrane to minimize post-laminectomy epidural adhesions and scarring. These outcomes have been associated with reduction in pain following these spinal procedures. In a rat model, amniotic membrane placed around the laminectomy site led to less epidural fibrosis adjacent to the dura and minimal scar tissue adherence to the dura. Similarly, cross-linked amniotic membrane covering the dura matter reduced fibroblast infiltration and scar tissue formation compared with animals receiving no treatment in a dog model of laminectomy.

In a clinical case study, 5 patients underwent transforminal lumbar interbody fusion with implantation of dHACM in the epidural space to observe effects on scarring and patient reported pain. After insertion of the interbody fusion device, bone graft material and posterior stabilization devices, the dHACM allograft was cut to fit the dura exposed by the decompression, and placed in the epidural space. Overall, minimal scarring in the epidural space and significantly lower patient pain scores post-surgery were reported. Of note, dHACM facilitated easy separation of the tissues in revision surgery for 4 of the 5 patients. Although in this study patient size was too small to evaluate the effectiveness of dHACM as a barrier membrane to prevent epidural fibrosis, it showed promising results in achieving that goal in future utilization of the allograft in vertebral spine fusion applications.

CONCLUSIONS

Amniotic membrane-based allografts are classified as a naturally derived biomaterial and are currently being used in wound and soft tissue repair applications. Characterization of this tissue has revealed many growth factors, cytokines, and protease inhibitors contained within dHACM tissue that can play a role in wound repair. dHACM has been shown to stimulate cellular activity including proliferation, migration, and secretion of soluble paracrine factors in vitro, and has also demonstrated the ability to recruit reparative adult stem cells to the site of dHACM implantation in vivo. In addition, these allografts have been shown in randomized clinical trials to be effective in healing various dermal and soft tissue wounds. Because of their regenerative properties, dHACM may also be used to repair and regenerate orthopedic tissues. To date, amniotic membrane and dHACM have been evaluated for repair of tendon and ligament, attenuation of cartilage and joint space diseases, and prevention of scarring and adhesion formation in spinal fusion procedures. dHACM allografts can be used both as a therapy to decrease pain and reduce fibrous tissue formation, for example in plantar fasciitis treatment, or as a supplement patch to a current procedure being performed, for example in spinal transforminal lumbar interbody fusion or ACL reconstruction. Clinical usage in orthopedic repair is rapidly growing and many ongoing clinical trials using dHACM allografts in plantar fasciitis treatments, Achilles tendon repair, lumbar decompression and microdiscectomy and total knee arthroplasty are underway (http://clinicaltrials.gov). Current research and clinical cases using amniotic membrane for repairing orthopedic tissues have shown that dHACM allografts can have promising results in repairing injured and diseased tissues due to their ability to deliver a natural ECM biomaterial that contains many active biomolecules. There is great potential for the use of amniotic membrane allografts for regenerative applications in orthopedics; however, much more research will be necessary to specifically define what those applications will be.

REFERENCES


